Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …

Cancer cells originate from a series of acquired genetic mutations that can drive their
uncontrolled cell proliferation and immune evasion. Environmental factors, including the …

Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with
antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but …

Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC
is its intimate association with the gut microbiota, which forms an essential part of the tumour …

The gut microbiota have long been recognized to play a key role in human health and
disease. Currently, several lines of evidence from preclinical to clinical research have …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

The intestinal barrier protects the host against gut microbes, food antigens, and toxins
present in the gastrointestinal tract. However, gut barrier integrity can be affected by intrinsic …

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented
responses in patients with high-risk hematologic malignancies. However, up to 60% of …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

The human microbiome constitutes a complex multikingdom community that symbiotically
interacts with the host across multiple body sites. Host-microbiome interactions impact …